Method Development and Validation for the Determination of Four Potential Impurities Present in Darunavir Tablets by Reverse Phase–Ultra-Performance Liquid Chromatography Coupled with Diode-Array Detector

References

• Robertson, J.; Feinberg, J. Darunavir: A Nonpeptidic Protease Inhibitor for Antiretroviral-Naive and Treatment-Experienced Adults with HIV Infection. Expert Opin. Pharmacother. 2012, 13 (9), 1363–1375.
   PubMed Web of Science ®Google Scholar
• Rakhmanina, N. Y.; Neely, M. N.; Capparelli, E. V. High Dose of Darunavir in Treatment-Experienced HIV-Infected Adolescent Results in Virologic Suppression and Improved CD4 Cell Count. Ther. Drug Monit. 2012, 34 (3), 237–241.
   PubMed Web of Science ®Google Scholar
• Leonis, G.; Czyżnikowska, Z.; Megariotis, G.; Reis, H.; Papadopoulos, M. G. Computational Studies of Darunavir into HIV-1 Protease and DMPC Bilayer: Necessary Conditions for Effective Binding and the Role of the Flaps. J. Chem. Inf. Model. 2012, 52 (6), 1542–1558.
   PubMed Web of Science ®Google Scholar
• Calcagno, A.; Yilmaz, A.; Cusato, J.; Simiele, M.; Bertucci, R.; Siccardi, M.; Marinaro, L.; D’Avolio, A.; Di Perri, G.; Bonora, S. Determinants of Darunavir Cerebrospinal Fluid Concentrations: Impact of Once-Daily Dosing and Pharmacogenetics. AIDS 2012, 26 (12), 1529–1533.
   PubMed Web of Science ®Google Scholar
• Correa, J. C.; D’Arcy, D. M.; Serra, C. H.; Salgado, H. R. A Critical Review of Properties of Darunavir and Analytical Methods for Its Determination. Crit. Rev. Anal. Chem. 2014, 44 (1), 16–22.
   PubMed Web of Science ®Google Scholar
• Djerada, Z.; Feliu, C.; Tournois, C.; Vautier, D.; Binet, L.; Robinet, A.; Marty, H.; Gozalo, C.; Lamiable, D.; Millart, H. Validation of a Fast Method for Quantitative Analysis of Elvitegravir, Raltegravir, Maraviroc, Etravirine, Tenofovir, Boceprevir and 10 Other Antiretroviral Agents in Human Plasma Samples With a New UPLC-MS/MS Technology. J. Pharm. Biomed. Anal. 2013, 86, 100–111.
   PubMed Web of Science ®Google Scholar
• D’Avolio, A.; Siccardi, M.; Sciandra, M.; Baietto, L.; Bonora, S.; Trentini, L.; Di Perri, G. HPLC-MS Method for the Simultaneous Quantification of the New HIV Protease Inhibitor Darunavir, and 11 Other Antiretroviral Agents in Plasma of HIV-Infected Patients. [Erratum to Document Cited in CA148:112145]. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2008, 862 (1–2), 265.
   Web of Science ®Google Scholar
• Nageswara Rao, R.; Ramachandra, B.; Santhakumar, K. RP-HPLC Separation and Characterization of Unknown Impurities of a Novel HIV-Protease Inhibitor Darunavir by ESIMS and 2D NMR Spectroscopy. J. Pharm. Biomed. Anal. 2013, 75, 186–191.
   PubMed Web of Science ®Google Scholar
• Kogawa, A. C.; Salgado, H. R. N. Development of Qualitative Analytical Methods for Monitoring Darunavir Tablets. Rev. Cienc. Farm. Basica Apl. 2013, 34 (2), 207–213.
   Google Scholar
• Reddy, M. P.; Ramireddy, N. Spectrophotometric Estimation of Darunavir in Bulk and Pharmaceutical Formulations. Int. J. Chem. Sci. 2013, 11 (1), 614–618.
   Google Scholar
• Correa, J. C. R.; dos Reis Serra, C. H.; Salgado, H. R. N. Stability Study of Darunavir Ethanolate Tablets Applying a New Stability-Indicating HPLC Method. Chromatogr. Res. Int. 2013, Article ID: 834173, 7 pp.
   Google Scholar
• Raveendra Babu, G.; Lakshmana Rao, A.; Venkateswara Rao, J. Development and Validation of Novel HPLC Method for Estimation of Darunavir in Pharmaceutical Formulations. Int. J. Res. Pharm. Chem. 2013, 3 (2), 438–443.
   Google Scholar
• Reddy, B. V. R.; Jyothi, G.; Reddy, B. S.; Raman, N. V. V. S. S.; Reddy, K. Chander, S.; Rambabu, C. Stability-Indicating HPLC Method for the Determination of Darunavir Ethanolate. J. Chromatogr. Sci. 2013, 51 (5), 471–476.
   PubMed Web of Science ®Google Scholar
• Patel, B. N.; Suhagia, B. N.; Patel, C. N. RP-HPLC Method Development and Validation for Estimation of Darunavir Ethanolate in Tablet Dosage Form. Int. J. Pharm. Pharm. Sci. 2012, 4 (3), 270–273.
   Google Scholar
• Patel, B. N.; Suhagia, B. N.; Patel, C.; Panchal, H. J. A Simple and Sensitive HPTLC Method for Quantitative Analysis of Darunavir Ethanolate Tablets. J. Planar Chromatogr.—Mod. TLC 2011, 24 (3), 232–235.
   Web of Science ®Google Scholar
• Patel, B. N.; Suhagia, B. N. Simultaneous Determination and Validation of Darunavir Ethanolate and Ritonavir in Binary Mixture by Liquid Chromatography. Int. J. Pharm. Technol. Res. 2012, 4 (4), 1450–1456.
   Google Scholar
• ICH. Validation of Analytical Procedures: Text and Methodology. Q2 (R1), 2005.
   Google Scholar
• ICH. Stability Testing of New Drug Substances and Products. Q1A (R2), 2005.
   Google Scholar
• US FDA Guidance. Analytical Procedures and Methods Validation. 2000.
   Google Scholar
• Official Methods of Analysis, 15th ed.; Association of Offical Analytical Chemists International: Arlington, VA, 1990; Authority of the Code of Federal Regulations: 9 CFR 318.19(b). Office of the Federal Register Washington, D.C., XVII.
   Google Scholar
• Validation of Compendial Methods <1225>. The United States Pharmacopeia. 2012.
   Google Scholar
• United States Pharmacopeial Convention, 36th ed.; The United States Pharmacopoeia: Rockville, MD, 2012.
   Google Scholar
• Guideline for Submitting Samples and Analytical Data for Methods Validation, US Food and Drug Administration, February 1987.
   Google Scholar
• Bliesner, D. M. Validating Chromatographic Methods: A Practical Guide. John Wiley & Sons, Inc.: Hoboken, New Jersey, 2006.
   Google Scholar
• Baertschi, S. W.; Alsante, K.; Reed, R. A. Pharmaceutical Stress Testing: Predicting Drug Degradation. Informa Healthcare, Telephone House, London, 2005.
   Google Scholar